Impact of Elexacaftor–Tezacaftor–Ivacaftor on Muscle Composition in Cystic Fibrosis: An AI-Assisted Chest CT-Based Body Composition Analysis
Medical Sciences · 2025
DOI: 10.3390/medsci13040284 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Medical Sciences, 2025. Verfasst von Matthias Welsner und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary Medicine, University Hospital Essen-Ruhrlandklinik, Adult Cystic Fibrosis Center, University of Duisburg-Essen, 45239 Essen, …. Hauptthemen laut MEDLINE: Aminophenols, Benzodioxoles, Cystic Fibrosis, Indoles. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
This study aimed to investigate longitudinal changes in muscle mass, quality, and composition (sarcopenia and myosteatosis) in adult people with cystic fibrosis (pwCF) using artificial intelligence (AI)-assisted body composition analysis (BCA) with chest computed tomography (CT) at the T12 level and to examine the influence of CFTR modulator therapy with elexacaftor/tezacaftor/ivacaftor (ETI).
Methods
A retrospective observational study was conducted on 102 adult pwCF (42 females (41%), mean age 33.9 ± 11.1 years) who underwent routine chest CT scans with a minimum of six months between scans. PwCF were categorized into ETI and no ETI groups. AI-assisted BCA was performed on chest CT images at the T12 level to measure skeletal muscle area (SMA), inter- and intramuscular adipose tissue (IMAT), and low-attenuation muscle area (LAMA). IMAT/SMA ratio and height- and weight-related skeletal muscle indices (SMI) were calculated.
Results
The ETI group showed a significant increase in SMA over time (p < 0.001), whereas the IMAT, LAMA, and IMAT/SMA ratio increased in both groups (all p < 0.05). SMI showed alterations only in the ETI group, with an increase in SMA/m2 (p < 0.001) and a decrease in SMA/kg (p = 0.003) and SMA/BMI (p = 0.006). Sex-specific analysis showed that SMA and myosteatosis increased regardless of sex (all p < 0.05). Weight-adjusted SMI decreased only in females receiving ETI therapy (p < 0.05).
Conclusions
Adult pwCF, particularly those undergoing ETI therapy, experience significant changes in body composition, including increased muscle mass and myosteatosis. Trends in the development of sarcopenic obesity have been observed, particularly in female pwCF. These findings emphasize the importance of comprehensive body composition assessments and targeted interventions in pwCF treated with ETI to optimize muscle mass and quality while managing adipose tissue accumulation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pulmonary Medicine, University Hospital Essen-Ruhrlandklinik, Adult Cystic Fibrosis Center, University of Duisburg-Essen, 45239 Essen, Germany.
- Pediatric Pulmonology and Sleep Medicine, Cystic Fibrosis Center, Children's Hospital, University of Duisburg-Essen, 45147 Essen, Germany.
- Institute for Artificial Intelligence in Medicine, University Medicine Essen, 45131 Essen, Germany.
- Institute of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, University of Duisburg-Essen, 45147 Essen, Germany.
ORCID-Profile: Matthias Welsner, Wolfgang Gruber, Erik Büscher, Felix Nensa, Sebastian Zensen, Michael Forsting, Johannes Haubold, Luca Salhöfer, Mathias Holtkamp, Judith Kohnke, Marcel Opitz
Zitieren
APA
Welsner, M., Stehling, F., Gruber, W., Westhölter, D., Sutharsan, S., Taube, C., Büscher, E., Nensa, F., Zensen, S., Umutlu, L., Forsting, M., Haubold, J., Salhöfer, L., Holtkamp, M., Kohnke, J., Hosch, R., & Opitz, M. (2025). Impact of Elexacaftor–Tezacaftor–Ivacaftor on Muscle Composition in Cystic Fibrosis: An AI-Assisted Chest CT-Based Body Composition Analysis. Medical Sciences. https://doi.org/10.3390/medsci13040284
Vancouver
Welsner M, Stehling F, Gruber W, Westhölter D, Sutharsan S, Taube C, et al. Impact of Elexacaftor–Tezacaftor–Ivacaftor on Muscle Composition in Cystic Fibrosis: An AI-Assisted Chest CT-Based Body Composition Analysis. Medical Sciences. 2025. doi:10.3390/medsci13040284
BibTeX
@article{Welsner2025,
author = {Welsner, Matthias and Stehling, Florian and Gruber, Wolfgang and Westhölter, Dirk and Sutharsan, Sivagurunathan and Taube, Christian and Büscher, Erik and Nensa, Felix and Zensen, Sebastian and Umutlu, Lale and Forsting, Michael and Haubold, Johannes and Salhöfer, Luca and Holtkamp, Mathias and Kohnke, Judith and Hosch, Rene and Opitz, Marcel},
title = {Impact of Elexacaftor–Tezacaftor–Ivacaftor on Muscle Composition in Cystic Fibrosis: An AI-Assisted Chest CT-Based Body Composition Analysis},
journal = {Medical Sciences},
year = {2025},
doi = {10.3390/medsci13040284}
}
EUVIMED